Related Experiment Video
Updated: Jul 3, 2026

Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System
Published on: May 24, 2017
Varenicline and its role in smoking cessation
1University of Illinois, Chicago, IL 60612, USA. shailendrakapoor@yahoo.com
Abstract:
Varenicline is a partial agonist of alpha4beta2 nicotinic receptors. It was recently approved for smoking cessation in the United States. It is administered at a dosage of 0.5 mg once a day for an initial period of 3 days followed by 0.5 mg twice a day for the next 4 days. Following this, the drug is administered at a dosage of 1.0 mg twice a day. The total duration of therapy is 12 weeks. Common adverse effects include nausea, headache, and insomnia. Recent studies show that varenicline is almost twice as effective as bupropion SR in smoking cessation. Given the increased risk of cardiovascular morbidity secondary to smoking, especially in the elderly, varenicline is a major therapeutic tool in the fight against smoking.
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
CNS Depressants: Alcohol and Nicotine
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Antidepressant Drugs: MAOIs and Other Agents
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
